Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 study

Journal of Clinical Oncology

Volumn 17, Issue 9, 1999, Pages 2659-2669

  Day, Richard ^a   Ganz, Patricia A ^a   Costantino, Joseph P ^a   Cronin, Walter M ^a   Wickerham, D Lawrence ^a   Fisher, Bernard ^a  

^a NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG INDUCED DISEASE; FEMALE; FEMALE SEXUAL DYSFUNCTION; FOLLOW UP; HUMAN; NORMAL HUMAN; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SELF REPORT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0032848782     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.9.2659     Document Type: Article

References (25)

1. Fisher B, Costantino JP, Wickerham L, et al: Tamoxifen for the prevention of breast cancer: A report from the NSABP P-1 study. J Natl Cancer Inst 90:1371-1388, 1998
2. Fisher B, Costantino J: Highlights of the NSABP Breast Cancer Prevention Trial. Cancer Control 4:78-86, 1997
3. Ganz PA, Day R, Ware JE, et al: Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst 87:1372-1382, 1995
4. Fisher B, Redmond C: Fraud in breast cancer trials. N Engl J Med 330:1458-1460, 1994
5. Fisher B, Anderson S, Redmond C, et al: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333:1456-1461, 1995
6. Ganz PA, Day R, Costantino JP: Compliance with quality of life data collection in the NSABP breast cancer prevention trial. Stat Med 17:613-622, 1998
7. Daniel WW: Applied Non-Parametric Statistics. Boston, MA, PWS-Kent Publishing Co, 1990
8. Deshpande JV, Gore AP, Shanubhougue A: Statistical Analysis of Non-Normal Data. New York, NY, John Wiley & Sons, 1995
9. International Resource Center for Health Care Assessment: How to Score the SF-36 Health Status Survey. Boston, MA, New England Medical Center, 1991
10. Radloff LS: The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1:385-401, 1977
11. Roberts RE, Vernon SW: The Center for Epidemiologic Studies Depression Scale: Its use in a community sample. Am J Psychiatry 140:41-46, 1983
12. Ware JE, Kosinski M, Keller SD: SF-36 Physical and Mental Summary Scales: A User's Manual (3rd Printing Revised). Boston, MA, The Health Institute, New England Medical Center, 1994
13. Fisher B: A commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. J Clin Oncol 14:1027-1039, 1996
14. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from NSABP B-14. J Natl Cancer Inst 86:527-537, 1994
15. Gorin MB, Day R, Costantino JP, et al: Long term tamoxifen citrate and potential ocular toxicity. Am J Ophthalmol 125:493-501, 1998
16. Hulley S, Grady D, Bush T, et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613, 1998
17. Cathacart CK, Jones SE, Pumroy CS, et al: Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 27:277-281, 1993
18. Love RL, Cameron L, Connell BL, et al: Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 151:1842-1847, 1991
19. Shariff S, Cumming CE, Lees A, et al: Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor antagonist: An unexpected effect? Ann N Y Acad Sci 761:365-368, 1995
20. Moredo Anelli T, Anelli A, Tran KN, et al: Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 74:74-77, 1994
21. Pluss JL, Dibella NJ: Reversible central nervous system dysfunction due to tamoxifen in a patient with breast cancer. Ann Intern Med 101:652, 1984
22. Robins LN, Heizer JE, Croughan J, et al: National Institute of Health Diagnostic Interview Schedule: Its history, characteristics and validity. Arch Gen Psychiatry 35:837-846, 1978
23. Burnam MA, Wells KB, Leake B, et al: Development of a brief screening instrument for detecting depressive disorders. Med Care 26:775-789, 1988
24. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996
25. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989